Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Insmed Incorporated (NasdaqNM:INSM)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Location
800 E. Leigh Street
Richmond, VA 23219
Phone: (804) 828-6893
Fax: (804) 828-6894
Email: investors@insmed.com
Employees (last reported count): 40
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 32%
·Over the last 6 months:
 · 2 insider sells; 18.0K shares
  (0.2% of insider shares)
·Institutional: 39% (58% of float)
(48 institutions)
·Net Inst. Buying: 1.52M shares (+10.50%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Insmed Incorporated is a biopharmaceutical company focused on the development of products to treat metabolic and endocrine-related conditions. The Company is currently developing INS-1, a naturally occurring, orally-active insulin sensitizer. It is being developed for Type 2 diabetes and Polycystic Ovary Syndrome (PCOS). To date in clinical trials, INS-1 has improved both ovulation rates in women with PCOS as well as glycemic and lipid profiles in patients with Type 2 diabetes. INS-1 is currently in Phase II clinical trials. The Company is also developing SomatoKine. Currently in Phase II clinical trials, SomatoKine is a human recombinant equivalent to the naturally occurring complex of the hormone, insulin-like growth factor-I (IGF-I) and its primary binding protein (IGFBP3). Results from a Phase II study indicate SomatoKine has the potential to amplify bone repair metabolism and functional recovery following hip fracture.
More from Market Guide: Expanded Business Description

Financial Summary
Insmed Incorporated is a biopharmaceutical company focused on the development of products to treat metabolic and endocrine-related conditions, and is currently developing an orally-active insulin sensitizer. For the six months ended 6/30/01, revenues rose 88% to $169 thousand. Net loss fell 72% to $18.9 million. Results reflect initial license fees from Taisho, partially offset by increased clinical trial and INS-1 manufacturing costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Geoffrey Allan, Ph.D., 47
Chairman, Pres, CEO
$714K$674K
Michael Baer, 56
CFO
270K54K
Robert Falconer, 48
VP Technical Operations
196K52K
Ronald Gunn, 40
VP-Bus. Devel.
246K401K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:INSMAs of 31-Aug-2001
Price and Volume
52-Week Low
on 8-Dec-2000
$2.563
Recent Price$4.01 
52-Week High
on 1-Sep-2000
$19.50 
Daily Volume (3-month avg)134.0K
Daily Volume (10-day avg)48.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-78.5%
52-Week Change
relative to S&P500
-71.1%
Share-Related Items
Market Capitalization$131.9M
Shares Outstanding32.9M
Float22.4M
Dividends & Splits
Annual Dividendnone 
Last Split: 1 for 4 on 31-July-2000
Per-Share Data
Book Value (mrq)$2.37 
Earnings (ttm)$
Earnings (mrq)-$0.27 
SalesN/A 
Cash (mrq)$2.03 
Valuation Ratios
Price/Book (mrq)1.69 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDAN/A 
Income available to common (ttm)$0 
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)0.00%
Return on Equity (ttm)0.00%
Financial Strength
Current Ratio (mrq)10.23 
Debt/Equity (mrq)0 
Total Cash (mrq)$66.9M
Short Interest
As of 8-Aug-2001
Shares Short545.0K
Percent of Float2.4%
Shares Short
(Prior Month)
675.0K
Short Ratio4.96 
Daily Volume110.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.